Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viridian Therapeutics Inc (NQ: VRDN )

20.86 +0.66 (+3.27%)
Streaming Delayed Price Updated: 12:43 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viridian Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
Analyst Ratings for Viridian Therapeutics
Via Benzinga
Recap: Viridian Therapeutics Q1 Earnings
Via Benzinga
Earnings Scheduled For May 9, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million. 
Via Benzinga
Earnings Outlook For Viridian Therapeutics
Via Benzinga
Expert Ratings for Viridian Therapeutics
Via Benzinga
Analyst Expectations for Viridian Therapeutics's Future
Via Benzinga
Viridian Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 17, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
Via Benzinga
Analyst Expectations for Viridian Therapeutics's Future
Via Benzinga
Viridian Therapeutics Earnings Preview
Via Benzinga
Earnings Scheduled For March 8, 2023
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million. 
Via Benzinga
The Latest Analyst Ratings for Viridian Therapeutics
Via Benzinga
Viridian's Thyroid Eye Disease Candidate Shows Promise At Lower Doses
Via Benzinga
Viridian Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
Via Benzinga
Viridian Therapeutics' Lead Product Has An Opportunity To Differentiate, Analyst Sees 85% Upside
Via Benzinga
Workday, XPeng, Titan Machinery And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2022
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
Via Benzinga
Why Horizon Therapeutics Shares Are Trading Higher By Over 30%; Here Are 32 Stocks Moving Premarket
Gainers Kalera Public Limited Company (NASDAQ: KAL) shares rose 33.3% to $0.2399 in pre-market trading after jumping 45% on Tuesday. Kalera recently announced restructuring process for German... 
Via Benzinga
Why Leslie's Shares Are Trading Lower By Over 9%? Here Are 60 Stocks Moving In Wednesday's Mid-Day Session
Gainers Biophytis S.A. (NASDAQ: BPTS) shares jumped 114% to $0.7496. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) rose 74.1% to $0.2115. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about for Wednesday! 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
At Higher Dose, Viridian's Thyroid Eye Disease Candidate Shows Significant, Rapid Improvement In Signs & Symptoms
Via Benzinga
Viridian Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Viridian Therapeutics (NASDAQ:VRDN) reported Q2 sales of $256 thousand. Earnings fell to a loss of $29.49 million, resulting in a 14.78% decrease from last quarter. 
Via Benzinga
Why Viridian's CEO Isn't Sweating His Company's Second-Place Position
The company didn't plan to be first in thyroid eye disease. But it hopes to be best. 
Via Investor's Business Daily
$10 Million Bet On This Casino Stock? 4 Stocks Insiders Are Buying
Although US stocks closed lower on Friday, there were a few notable insider trades. 
Via Benzinga
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.